Key result
Simultaneous aortic valve replacement during LVAD implantation in unstable patients (INTERMACS 1-2) was associated with significantly increased in-hospital mortality compared to LVAD alone, but did not impair outcomes in stable patients.
Why the study?
Aortic valve regurgitation or mechanical aortic valve prosthesis is a relative contraindication for LVAD implantation, but concomitant aortic valve replacement with a biological prosthesis is an option with limited outcome data.
Cohort (n=318)
No
Answers are grounded in this paper and cite their sources.
Simultaneous AVR may raise mortality in unstable LVAD patients; leaves open its safety in stable patients pending prospective data.
INTRODUCTION: Aortic valve regurgitation or the presence of a mechanical aortic valve prosthesis is a relative contraindication for implantation of left ventricular assist devices (LVAD). However, concomitant aortic valve replacement by a biological prosthesis is one of the options in this situation. We analyzed our recent experience with left ventricular assist device implantation and concomitant aortic valve replacement. METHODS: Between January 1, 2008 and January 15, 2012, 318 adult patients (>18 years old) were supported with a long-term implantable LVAD in our institution. In 19, simultaneous aortic valve replacement (6 redo and 13 primary procedures) was performed. Patients were divided into 2 groups according to INTERMACS (IM) level: Group 1 (n = 7) consisted of patients with IM level 1-2 and Group 2 (n = 12) of IM level 3-4 patients. As a control cohort we analyzed all LVAD recipients during the study period (n = 299, study group excluded). The control cohort was similarly divided into two groups according to the IM level: Group 3 (n = 162) consisted of patients with IM level 1-2 and Group 4 (n = 137) of those with IM level 3-5. Perioperative data and outcomes in all groups were retrospectively analyzed and compared (Group 1 compared to Group 3; and Group 2 to Group 4). RESULTS: In study Groups 1 and 2 all patients were male; in Groups 3 and 4, 80% and 88% respectively were male. Median age distribution in Groups was 55, 61, 54, and 57 years respectively. Patients from Group 2 were significantly older than those from Group 4 (p = 0.039). Body mass index was significantly lower in Group 1 than in Group 3 (p = 0.033). Cardio-pulmonary bypass time was significantly longer in Groups 1 and 2 compared with Groups 3 and 4 respectively (p=0.001). Patients from Group 1 had a trend more often to develop right ventricular failure requiring a right ventricular assist device (RVAD) than those in Group 3 (p = 0.09). Intensive care unit stay duration of mechanical ventilation and in-hospital mortality in Group 1 were significantly higher than in Group 3 (p = 0.025, p = 0.005, p = 0.038). Patients from Group 2 had similar outcomes compared to those from Group 4. CONCLUSIONS: In stable patients, simultaneous aortic valve replacement and LVAD implantation are not associated with an impaired outcome. In patients with cardiogenic shock an additional aortic valve replacement may impair outcome; therefore alternative techniques should be considered.
No takes yet. Share an insight, caveat, or question.
Dranishnikov et al. (2012) conducted a cohort in End-stage heart failure requiring LVAD (n=318). Simultaneous aortic valve replacement and LVAD implantation vs. LVAD implantation alone was evaluated on In-hospital mortality (INTERMACS level 1-2 patients) (p=0.038). Simultaneous aortic valve replacement during LVAD implantation in unstable patients (INTERMACS 1-2) was associated with significantly increased in-hospital mortality compared to LVAD alone, but did not impair outcomes in stable patients.
Synapse has enriched 10 related papers. Consider them for comparative context: